Literature DB >> 12791771

The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappaB.

Sebastien P Tabruyn1, Catherine M Sorlet, Francoise Rentier-Delrue, Vincent Bours, Richard I Weiner, Joseph A Martial, Ingrid Struman.   

Abstract

We have previously shown that the 16-kDa N-terminal fragment of human prolactin (16K hPRL) has antiangiogenic properties, including the ability to induce apoptosis in vascular endothelial cells. Here, we examined whether the nuclear factor-kappaB (NF-kappaB) signaling pathway was involved in mediating the apoptotic action of 16K hPRL in bovine adrenal cortex capillary endothelial cells. In a dose-dependent manner, treatment with 16K hPRL induced inhibitor kappaB-alpha degradation permitting translocation of NF-kappaB to the nucleus and reporter gene activation. Inhibition of NF-kappaB activation by overexpression of a nondegradable inhibitor kappaB-alpha mutant or treatment with NF-kappaB inhibitors blocked 16K hPRL-induced apoptosis. Treatment with 16K hPRL activated the initiator caspases-8 and -9 and the effector caspase-3, all of which were essential for stimulation of DNA fragmentation. This activation of the caspase cascade by 16K hPRL was also NF-kappaB dependent. These findings support the conclusion that NF-kappaB signaling plays a central role in 16K hPRL-induced apoptosis in vascular endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12791771     DOI: 10.1210/me.2003-0132

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  23 in total

Review 1.  16-kDa prolactin and bromocriptine in postpartum cardiomyopathy.

Authors:  Denise Hilfiker-Kleiner; Ingrid Struman; Melanie Hoch; Edith Podewski; Karen Sliwa
Journal:  Curr Heart Fail Rep       Date:  2012-09

Review 2.  Pathophysiology and epidemiology of peripartum cardiomyopathy.

Authors:  Denise Hilfiker-Kleiner; Karen Sliwa
Journal:  Nat Rev Cardiol       Date:  2014-04-01       Impact factor: 32.419

3.  Prolactin/growth hormone-derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis.

Authors:  Ngoc-Quynh-Nhu Nguyen; Sebastien P Tabruyn; Laurence Lins; Michelle Lion; Anne M Cornet; Florence Lair; Francoise Rentier-Delrue; Robert Brasseur; Joseph A Martial; Ingrid Struman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-14       Impact factor: 11.205

Review 4.  Role of pregnancy hormones and hormonal interaction on the maternal cardiovascular system: a literature review.

Authors:  Vitaris Kodogo; Feriel Azibani; Karen Sliwa
Journal:  Clin Res Cardiol       Date:  2019-02-26       Impact factor: 5.460

5.  Regulation of Tumor Angiogenesis and Choroidal Neovascularization by Endogenous Angioinhibitors.

Authors:  Venugopal Gunda; Yakkanti A Sudhakar
Journal:  J Cancer Sci Ther       Date:  2013-07-04

6.  Acurhagin-C, an ECD disintegrin, inhibits integrin alphavbeta3-mediated human endothelial cell functions by inducing apoptosis via caspase-3 activation.

Authors:  Wen-Jeng Wang
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

7.  PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin.

Authors:  Khalid Bajou; Stephanie Herkenne; Victor L Thijssen; Salvino D'Amico; Ngoc-Quynh-Nhu Nguyen; Ann Bouché; Sébastien Tabruyn; Mohammed Srahna; Jean-Yves Carabin; Olivier Nivelles; Cécile Paques; Ivo Cornelissen; Michelle Lion; Agnès Noel; Ann Gils; Stefan Vinckier; Paul J Declerck; Arjan W Griffioen; Mieke Dewerchin; Joseph A Martial; Peter Carmeliet; Ingrid Struman
Journal:  Nat Med       Date:  2014-06-15       Impact factor: 53.440

Review 8.  Role of prolactin and vasoinhibins in the regulation of vascular function in mammary gland.

Authors:  Carmen Clapp; Stéphanie Thebault; Gonzalo Martínez de la Escalera
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-19       Impact factor: 2.673

9.  MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy.

Authors:  Julie Halkein; Sebastien P Tabruyn; Melanie Ricke-Hoch; Arash Haghikia; Ngoc-Quynh-Nhu Nguyen; Michaela Scherr; Karolien Castermans; Ludovic Malvaux; Vincent Lambert; Marc Thiry; Karen Sliwa; Agnes Noel; Joseph A Martial; Denise Hilfiker-Kleiner; Ingrid Struman
Journal:  J Clin Invest       Date:  2013-04-24       Impact factor: 14.808

10.  Novel fusion protein derived from vasostatin 30 and vasoinhibin II-14.1 potently inhibits coronary endothelial cell proliferation.

Authors:  Gabriela Vazquez Rodriguez; Carmen Gonzalez; Antonio De Leon Rodriguez
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.